India’s Council of Scientific and Industrial Research (CSIR) seek creative ways to combat the novel coronavirus known as COVID-19. They suspect that Sepsivac—a commercial drug used for patients with gran-negative sepsis, may hold some promise.
What is the angle with this drug?
First, cytokines, defense agents in the human body, respond and fight invading pathogens. With six different kinds of cytokines and each type has a mix of families and substances, a cytokine profile equals a specific mix of cytokines. Different cytokine profiles act differently on different pathogens.
COVID-19 triggers cytokine storms which are very dangerous for the infected person. When this occurs, the human body triggers a violent immune response generating surplus cytokines—the process does great damage and of course can lead to death. Moreover, the tissue damage can lead to sepsis.
What is Gram-negative sepsis?
This occurs when dangerous gram-negative bacterial let toxins in the blood—the body reacts with defensive agents to mitigate the toxin’s effects but of course end up damaging the body. Patients impacted by gram-negative sepsis under a cytokine storm.
What is Sepsivac used for?
This drug is used to modulate the immune system by lessening the probability of the cytokine storm and, hence, reducing the chances for mortality while generally improving the healing process.
CSIR investigators note the similarities between the clinical characteristics of COVID-19 patient symptoms and gram-negative sepsis and now collaborate on initiating a randomized, blinded, controlled clinical trial to investigate Sepsivac’s efficacy to lessen the probability of mortality in critically ill SARS-CoV-2 infected patients.
This study has been approved by the Drug Controller General of India and will now move to multiple hospitals (sites) around India.
Who is the drug maker?
Cadilla Pharmaceuticals. They are one of the largest privately-held pharmaceutical companies in India. The company has been operating for the past six decades.